In this webinar, we explore the challenges of assessing the immunosafety profile when moving a drug candidate to first-in-human studies. Our expert shares key considerations and pitfalls to avoid along the way. Case studies highlight how in vitro immunotoxicity assessments add significant value by predicting risk early. This knowledge allows for modifications to the candidate or package design to mitigate risk and increase the likelihood of a successful study.
You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center